MedTrace Logo

The Role of CD34 + Stem Cells and Biomarkers in the Development of CAV in HTX Patients

NCT05485467 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2023-11-08

No results posted yet for this study

Summary

Coronary allograft vasculopathy represents one of the major limiting factors of long-term survival in heart transplant recipients. While extensively researched, the underlying mechanisms of coronary allograft vasculopathy (CAV) after heart transplantation remain incompletely understood. As CD34+ cells represent one of the key determinants of coronary vascular homeostasis we investigated the potential association between CAV and CD34+ cell count in heart transplant recipients.

Conditions

  • Vasculopathy
  • Heart Transplant Failure

Interventions

DIAGNOSTIC_TEST

coronary CT angiography

Coronary CT angiography will be performed on multislice Siemens Somat Force CT scanner

Sponsors & Collaborators

  • University Medical Centre Ljubljana

    lead OTHER

Principal Investigators

  • Gregor Poglajen, MD, PhD · Advanced Heart Failure and Transplantation Center, Dept. of Cardiology, University Medical Center Ljubljana, Slovenia

  • Bojan Vrtovec, MD, PhD · [email protected]

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2022-08-15
Completion
2022-08-31

Countries

  • Slovenia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05485467 on ClinicalTrials.gov